Osteopathic Medical Oncology and Hematology, P.C. v. Commissioner

113 T.C. No. 26
CourtUnited States Tax Court
DecidedNovember 22, 1999
Docket11551-98
StatusUnknown

This text of 113 T.C. No. 26 (Osteopathic Medical Oncology and Hematology, P.C. v. Commissioner) is published on Counsel Stack Legal Research, covering United States Tax Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Osteopathic Medical Oncology and Hematology, P.C. v. Commissioner, 113 T.C. No. 26 (tax 1999).

Opinion

113 T.C. No. 26

UNITED STATES TAX COURT

OSTEOPATHIC MEDICAL ONCOLOGY AND HEMATOLOGY, P.C., Petitioner v. COMMISSIONER OF INTERNAL REVENUE, Respondent

Docket No. 11551-98. Filed November 22, 1999.

P, a professional service corporation, specializes in the treatment of cancer through chemotherapy. P uses drugs and ancillary pharmaceuticals (collectively, the drugs) during its treatment. The chemotherapy treatments are prescribed by P’s professional staff, and patients do not select the type or quantity of drugs used during the treatments. P uses the cash method to expense the cost of the drugs. R determined that the drugs were "merchandise" under sec. 1.471-1, Income Tax Regs., and that P must use an accrual method to report all amounts attributable to the drugs. Held: The inherent nature of P's business is that of a service provider, P’s use of the drugs is subordinate to the provision of its services, and P uses the drugs as an indispensable and inseparable part of the rendering of its services; thus, the drugs are not "merchandise" under sec. 1.471-1, Income Tax Regs., and P properly used the cash method to expense the drugs’ cost. - 2 -

David C. May, for petitioner.

Grant E. Gabriel, for respondent.

OPINION

LARO, Judge: The parties submitted this case to the Court

without trial. See Rule 122. Petitioner petitioned the Court to

redetermine respondent's determination of a $50,515 deficiency in

its 1995 Federal income tax. The sole issue for decision is

whether petitioner, a professional service corporation, may use

the cash receipts and disbursements method (cash method) to

expense the drugs and ancillary pharmaceuticals (collectively,

chemotherapy drugs) used by it while providing chemotherapy

treatments to its patients. We hold it may. Unless otherwise

stated, section references are to the Internal Revenue Code as

applicable to 1995, and Rule references are to the Tax Court

Rules of Practice and Procedure.

Background

All facts are stipulated and are so found. The stipulation

of facts and exhibits submitted therewith are incorporated herein

by this reference. Petitioner's principal place of business was

in Clinton Township, Michigan, when it petitioned the Court.

Petitioner is a professional medical corporation that

provides osteopathic services, with a speciality in oncology

(mainly chemotherapy) and hematology. Petitioner's staff - 3 -

consists of physicians, nurses and nursing assistants, laboratory

technicians, administrative personnel, and office workers.

Petitioner has three offices in the Clinton Township area. At

each of these offices, petitioner stores chemotherapy drugs and

has the staffing, equipment, and supplies necessary to administer

chemotherapy treatments.

Chemotherapy drugs are pharmaceutical drugs which under

applicable State (Michigan) law must be prescribed by a doctor

and may be sold only by a licensed pharmacist. Petitioner is not

a licensed pharmacist, and it is unlawful for petitioner to sell

the drugs. Petitioner may use the drugs during the performance

of its chemotherapy services.

Chemotherapy drugs come in ready-to-use form or as powders

or liquids that require mixing. Petitioner generally maintains

about a 2-week supply of chemotherapy drugs, and it regularly

purchases chemotherapy drugs from suppliers to insure that it has

enough on hand to administer prescribed treatments. Chemotherapy

drugs, in an unmixed form, have shelf-lives varying from about 6

months to 1 year.

When an individual first becomes a patient of petitioner,

one of petitioner's physicians examines him or her to prescribe

necessary treatments, and that physician records the

individualized chemotherapy treatment in the patient's file.

After the patient is evaluated and the physician prescribes a - 4 -

chemotherapy regime, the patient begins regular, periodic

treatments. The patient does not select the type or quantity of

drugs used in the treatments; this selection is within the sole

discretion of petitioner’s professional staff. In accordance

with standard oncology practice, patients are not examined by a

physician at every chemotherapy treatment but are usually

reexamined by a physician every 4 to 6 weeks during the ongoing

course of treatments. Any changes in the future course of

treatments are documented in the patient's file at that time.

Petitioner's personnel mix and otherwise prepare the

chemotherapy drugs that petitioner administers to a patient; the

chemotherapy drugs cannot be self-administered. One of

petitioner's oncology nurses generally performs the

administration, and a physician is always on site to respond to

emergencies. The physician is not always in the room during the

administration.

Petitioner is a participating provider with Medicare1 and

several other private insurance carriers. Virtually all of

petitioner's patients who receive chemotherapy treatments are

covered by Medicare or private insurance, and those patients are

billed only for the cost of the treatments to the extent of

co-payments, deductibles, and other uncovered charges. For each

1 See Health Insurance for Aged Act, Pub. L. 89-97, 79 Stat. 291 (1965), currently codified at 42 U.S.C. secs. 1395 through 1395ccc (1994). - 5 -

patient visit, petitioner's staff prepares a physician's

statement known as a "charge sheet", which is the document from

which petitioner's billing department generates its bills. The

charge sheet specifically lists the type, amount, and cost of

chemotherapy and other drugs administered, and the type and cost

of all professional services rendered. The charge sheets are

specific as to the particulars of chemotherapy treatments so as

to comply with the guidelines of Medicare and the private

insurance industry. Petitioner submits the charge sheets

directly to Medicare or other responsible party, and petitioner

bills its patients for the copayments or other charges not

covered by insurance.

Medicare and private insurers analyze on an item-by-item

basis whether to reimburse the charges shown on the charge

sheets. The dollar amount reimbursed for a drug administered to

a patient is ascertained by reference to the average wholesale

price (AWP) of the units in which the drug is packaged and sold

wholesale, which AWP is published annually with quarterly

updates. Generally, the reimbursement amount for drugs equals

the AWP times the units used, with rounding up to the next whole

unit of a drug when billing for administration of a partial unit.

It is common industry practice to charge for all medical

services provided even when the health care provider anticipates

it will not be paid in full for all charges. The standard charge - 6 -

nationally for chemotherapy drugs is 1.5 times the AWP, and

petitioner bills its patients for the drugs at this rate with the

expectation that the patient will pay the excess over the amount

reimbursed. With all reimbursement payments from Medicare or

private insurers, petitioner receives an "Explanation of

Benefits" that details the amounts allowed and disallowed as to

each specific charge, and the amounts for each charge which are

due from secondary insurance and/or the patient.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Thor Power Tool Co. v. Commissioner
439 U.S. 522 (Supreme Court, 1979)
Commissioner v. Asphalt Products Co.
482 U.S. 117 (Supreme Court, 1987)
Indopco, Inc. v. Commissioner
503 U.S. 79 (Supreme Court, 1992)
Knight-Ridder Newspapers, Inc. v. United States
743 F.2d 781 (Eleventh Circuit, 1984)
American Fletcher Corporation v. United States
832 F.2d 436 (Seventh Circuit, 1987)
Hospital Corp. of Am. v. Commissioner
1996 T.C. Memo. 105 (U.S. Tax Court, 1996)
Wal-Mart Stores v. Commissioner
1997 T.C. Memo. 1 (U.S. Tax Court, 1997)
Ansley-Sheppard-Burgess Co. v. Commissioner
104 T.C. No. 17 (U.S. Tax Court, 1995)
Hospital Corp. of Am. v. Commissioner
107 T.C. No. 8 (U.S. Tax Court, 1996)
St. Luke's Hospital, Inc. v. Commissioner
35 T.C. 236 (U.S. Tax Court, 1960)
Fusz v. Commissioner
46 T.C. 214 (U.S. Tax Court, 1966)
Gulf Oil Corp. v. Commissioner
89 T.C. No. 70 (U.S. Tax Court, 1987)

Cite This Page — Counsel Stack

Bluebook (online)
113 T.C. No. 26, Counsel Stack Legal Research, https://law.counselstack.com/opinion/osteopathic-medical-oncology-and-hematology-pc-v-commissioner-tax-1999.